Developer docs
API playgroundTry for free, no card

Search company profiles

Pfizer Malaysia

Full company profile

uuid0053kte

Namestring
Pfizer Malaysia
Legal namestring
Pfizer Malaysia Sdn Bhd
Websiteurl
pfizer.com.my
Company typeenum
Private
Founded yearint
1978
Descriptiontext

Pfizer Malaysia Sdn Bhd is the Malaysian operating subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Incorporated in Malaysia in 1978 and headquartered in Bangsar South, Kuala Lumpur with a lean 46-employee team, the company develops, markets, and distributes innovative prescription medicines, vaccines, and consumer health products across therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine, and Rare Disease. The portfolio spans established hospital products such as the Zavicefta antibiotic (ceftazidime/avibactam), the Pfizer-BioNTech COVID-19 vaccine supplied under the National Immunization Program via JKJAV, pneumococcal vaccines for adult and pilgrimage populations, and an industry-leading oncology portfolio of 22 approved cancer medicines across 30+ indications. The company also operates patient assistance programmes such as ALKare PLUS for ALK-positive NSCLC patients, digital therapeutics platforms in partnership with DoctorOnCall, and the Care-A-Van mobile community health screening programme that has reached over 156,000 lives across 800 locations over 22 years.

Pfizer Malaysia's business model is built on enterprise field sales to hospitals, clinics, and pharmacies, complemented by direct government vaccine supply contracts, partnerships with telehealth platforms (DoctorOnCall) and consumer financing partners (UOB Malaysia), and a layer of patient assistance and disease awareness programs delivered jointly with Malaysian patient advocacy organizations (LCNM, NCSM, BCWA, MTS, MRCS). Revenue mechanics are one-time license-style sales of prescription pharmaceuticals and vaccines, with pricing not publicly disclosed and patient cost addressed through programs such as ALKare PLUS and the ASK4VACCINE 12-month interest-free instalment plan. Customer segments span healthcare providers, government (JKJAV / Ministry of Health for COVID-19 vaccination), and patient populations including ALK-positive NSCLC patients, metastatic breast cancer patients and caregivers, Hajj and Umrah pilgrims, older adults aged 50+, and B40 underserved communities.

The company is led by Country Manager Luksanawan Thangpaibool (also covering Brunei) and Country Medical Director Dr. Jerusha Naidoo. It draws on the parent Pfizer Inc.'s global R&D infrastructure (25,000 clinical researchers) and benefits from Pfizer's 170+ year brand heritage and 2023 Fortune recognitions including World's Most Admired Companies All-Stars, World's Best Companies, Best Employers for New Grads, and Equality 100 Award. Geographic scope is single-country domestic, with distribution routed through direct sales, government health programs, and channel partnerships.

Short descriptiontext

Pfizer Malaysia Sdn Bhd, the Malaysian subsidiary of Pfizer Inc., develops and commercializes innovative prescription medicines, vaccines, and patient assistance programs across oncology, vaccines, internal medicine, and rare disease for healthcare providers, government, and patients in Malaysia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKuala Lumpur, Malaysia
HQ citystring
Kuala Lumpur
HQ countrystring
Malaysia
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, biopharmaceutical medicines, vaccine products, cancer therapeutics, patient assistance programs
Industry3 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAJAG
Vaccines & Cold-Chain Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRAOAHAI
Vaccines & Public Health Product Distribution
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Medicines
TypeOne Time License
Description

Pfizer develops and sells innovative prescription medicines across therapeutic areas including Oncology, Inflammation & Immunology, Internal Medicine, and Rare Disease. Revenue generated through direct sales to healthcare providers and pharmacies.

pfizer.com.my
2Vaccines
TypeOne Time License
Description

Pfizer manufactures and distributes vaccines including pneumococcal vaccines and COVID-19 vaccine. Revenue generated through government contracts and healthcare provider sales.

pfizer.com.my
3Consumer Health Care Products
TypeOne Time License
Description

Pfizer offers consumer healthcare products as part of its global portfolio alongside prescription medicines and vaccines.

pfizer.com.my
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pfizer Malaysia develops, markets, and distributes innovative prescription medicines and vaccines to healthcare providers, pharmacies, and government health programs in Malaysia. Its portfolio spans Oncology, Inflammation & Immunology, Internal Medicine, Rare Disease, and Vaccines, including specific products such as the Zavicefta antibiotic for serious Gram-negative bacterial infections and COVID-19 and pneumococcal vaccines supplied through the National Immunization Program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 156,000+ lives touched through Care-A-Van mobile health screening program across 800 locations
+1 more record
Product overview1 text field

Pfizer Malaysia operates as a biopharmaceutical company within the Pfizer global network, offering a portfolio of innovative medicines, vaccines, and digital health solutions. The product portfolio includes pharmaceutical products (antibiotics such as Zavicefta), patient assistance programmes (ALKare PLUS for lung cancer patients), and mobile/community health services (Care-A-Van reaching 156,000+ lives). Pfizer Malaysia also provides digital health platforms developed in partnership with DoctorOnCall, patient education resources including the Me & mBC guide for metastatic breast cancer and lung cancer patient handbook, and disease prevention platforms like PreventPneumonia.com.my. The company focuses on therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine, and Rare Disease, serving healthcare professionals, patients, and the Malaysian community through integrated digital and physical health programmes.

Product and service6 records
1Zavicefta (ceftazidime/avibactam)
CategoryPrescription pharmaceutical (antibiotic)
Description

Novel combination antibiotic combining ceftazidime (third-generation antipseudomonal cephalosporin) with avibactam (beta-lactamase inhibitor) for treating serious Gram-negative bacterial infections in hospitalised adults aged 18 years and above. Indicated for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), Hospital-Acquired Pneumonia (HAP), and Ventilator Associated Pneumonia (VAP).

2ALKare PLUS Patient Assistance Programme
CategoryPatient assistance programme
Description

Patient assistance programme that helps ALK-positive advanced non-small cell lung cancer (NSCLC) patients in Malaysia access and continue innovative targeted therapies through financial support, treatment continuity planning, and education services.

3Care-A-Van Mobile Health Screening Programme
CategoryCommunity health service
Description

Mobile community health screening and outreach programme delivering healthcare awareness and basic health services to underserved and underprivileged communities in Malaysia. Has reached more than 156,000 lives across 800 locations over 22 years and covers breast health, mental health, and disease prevention education.

4Pfizer-BioNTech COVID-19 Vaccine (Malaysian supply)
CategoryVaccine
Description

Pfizer-BioNTech COVID-19 vaccine supplied to Malaysia through a partnership with JKJAV (Special Committee for Ensuring Access to Covid-19 Vaccine Supply) for deployment under the National Covid-19 Immunization Program, administered via government health channels and partner providers.

5ASK4VACCINE Pneumococcal Vaccination Programme
CategoryVaccination financing programme
Description

Pneumococcal vaccination access programme that enables Malaysian parents to obtain paediatric pneumococcal vaccination with a 12-month interest-free instalment payment plan when paying via UOB Malaysia credit cards, addressing affordability barriers to childhood immunisation.

6Pneumococcal Vaccines (Prevenar family) for Hajj/Umrah Pilgrims and Older Adults
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-30
Description

Partnership in University For Society (U4S) Central Zone program. UM focuses on Building Resilience for Society with mental health webinars and Construction Skills Training Module for youth community.

2Universiti Teknologi MARA (UiTM)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-30
Description

Partnership in U4S Central Zone program. UiTM runs Financial Independence Strategy for Community Entrepreneur (FISCENT) project with business networking and workshop programs.

pfizer.com.my
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-30
Description

Partnership in U4S Central Zone program. IIUM runs Creative Youth (CR8V Youth) project and Integrated and Sustainable Agriculture Farming (InSAF) project.

4BUMITRA Malaysia
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2021-11-11
Description

MOU to drive pneumococcal disease prevention awareness among Hajj and Umrah pilgrims. Campaign uses BUMITRA Malaysia Facebook page to provide information about pneumococcal pneumonia through comics, posters, infographics, and animated videos.

pfizer.com.my
5Lung Cancer Network Malaysia (LCNM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Partnership with LCNM and NCSM to launch Malaysia's first digital lung cancer patient handbook. The #KeepBreathing campaign improves public understanding of lung cancer and addresses misconceptions about the disease.

pfizer.com.my
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Partnership with NCSM to develop Malaysia's first digital lung cancer patient handbook to improve health literacy and facilitate better communication between patients and healthcare providers.

7Breast Cancer Welfare Association Malaysia (BCWA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-07
Description

Support for #UNPAUSE 2021 campaign celebrating and recognizing cancer caregivers. Launch of Me & mBC digital guide and audiobook to improve metastatic breast cancer literacy and patient-caregiver communication.

pfizer.com.my
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-11
Description

Partnership for 'Mental Health for All' digital campaign addressing mental health concerns in Malaysia. Provides resources on mental health conditions, self-assessment quizzes, and connects users to mental health specialists via tele-consult.

9JKJAV (Special Committee for Ensuring Access to Covid-19 Vaccine Supply)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Partnership with JKJAV under Ministry of Health and Ministry of Science, Technology and Innovation for supply and implementation of Pfizer-BioNTech COVID-19 vaccine in National Immunization Program.

pfizer.com.my
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-16
Description

Malaysia's first tripartite collaboration between DoctorOnCall, Pfizer, and UOB Malaysia. The ASK4VACCINE program enables Malaysian parents to provide pneumococcal vaccination for children via a 12-month interest-free instalment payment plan for UOB Malaysia credit card holders.

11Malaysian Thoracic Society (MTS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-28
Description

Launch of 'You Are Our Best Shot' campaign to normalize adult vaccination and improve health literacy for higher vaccination uptake among older adults. Includes digital resource hub at preventpneumonia.com.my.

pfizer.com.my
12Malaysian Red Crescent Society (MRCS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-16
Description

MOU to provide psychosocial support for Malaysians dealing with COVID-19 pandemic challenges. Programs include RedCrescent4u Careline, Care-A-Van x MyVac program for health screening in rural areas, and health webinars. Care-A-Van has touched 156,000+ lives across 800 locations.

pfizer.com.my
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-05
Description

Pfizer collaborated with DoctorOnCall to launch a digital therapeutics platform focusing on three key therapeutic areas: smoking cessation, vaccination, and heart health. The platform includes health centers with educational content, engagement tools, and free doctor consultations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sanofi Malaysia is the Malaysian subsidiary of Sanofi, a peer multinational pharmaceutical company. Both Pfizer Malaysia and Sanofi Malaysia operate in vaccines, specialty care, and consumer health with similar hospital and pharmacy go-to-market models.

2Johnson & Johnson Malaysia
TypeDirect peer
Description

Johnson & Johnson Malaysia is the Malaysian subsidiary of J&J, operating across pharmaceuticals, medical devices, and consumer health. It is a close peer to Pfizer Malaysia given overlapping therapeutic areas and similar commercial model targeting hospitals and specialists.

TypeDirect peer
Description

AstraZeneca Malaysia is the Malaysian subsidiary of AstraZeneca, a peer global biopharmaceutical company. Both compete in oncology, respiratory, and vaccine categories through hospital and government channels in Malaysia.

TypeDirect peer
Description

Novartis Malaysia is the Malaysian arm of Novartis, another large multinational pharma with presence in oncology, cardiovascular, and immunology. It competes directly with Pfizer Malaysia across specialty therapeutics and hospital sales channels in Malaysia.

5Merck Sharp & Dohme (MSD) Malaysia
TypeDirect peer
Description

MSD Malaysia is the Malaysian subsidiary of Merck & Co., a direct peer in oncology, vaccines, and specialty therapeutics. Both target similar hospital, government, and pharmacy customers with comparable global pharma playbooks.

6Boehringer Ingelheim Malaysia
TypeDirect peer
Description

Boehringer Ingelheim Malaysia is the Malaysian arm of Boehringer Ingelheim, a multinational pharma peer focused on respiratory, cardiometabolic, and specialty therapeutics. It competes with Pfizer Malaysia for hospital channel share in similar specialty care segments.

TypeDirect peer
Description

Bayer Malaysia is the Malaysian subsidiary of Bayer, a comparable multinational pharma with presence in pharmaceuticals, consumer health, and animal health. It is a relevant peer given overlap in cardiovascular and women's health therapeutic areas.

TypeDirect peer
Description

Eli Lilly Malaysia is the Malaysian subsidiary of Eli Lilly, a multinational pharma peer with growing emphasis on oncology, diabetes, and immunology. Both compete for the same specialty prescriber audience in Malaysia's hospital channel.

TypeDirect peer
Description

GSK Malaysia is the Malaysian subsidiary of GSK, a direct peer with a comparable vaccines and specialty pharmaceuticals portfolio. Both compete head-to-head in adult and travel vaccination markets and consumer health adjacencies in Malaysia.

TypeDirect peer
Description

Roche Malaysia is the Malaysian subsidiary of Roche Holding, a peer multinational pharmaceutical company. Both are wholly-owned subsidiaries of global pharma majors operating in Malaysia with oncology, specialty therapeutics, and biologics portfolios, targeting the same hospital and government channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pfizer Malaysia

Pharmaceuticalspfizer.com.my

Pfizer Malaysia Sdn Bhd, the Malaysian subsidiary of Pfizer Inc., develops and commercializes innovative prescription medicines, vaccines, and patient assistance programs across oncology, vaccines, internal medicine, and rare disease for healthcare providers, government, and patients in Malaysia.

What Pfizer Malaysia does

Pfizer Malaysia Sdn Bhd is the Malaysian operating subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Incorporated in Malaysia in 1978 and headquartered in Bangsar South, Kuala Lumpur with a lean 46-employee team, the company develops, markets, and distributes innovative prescription medicines, vaccines, and consumer health products across therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine, and Rare Disease. The portfolio spans established hospital products such as the Zavicefta antibiotic (ceftazidime/avibactam), the Pfizer-BioNTech COVID-19 vaccine supplied under the National Immunization Program via JKJAV, pneumococcal vaccines for adult and pilgrimage populations, and an industry-leading oncology portfolio of 22 approved cancer medicines across 30+ indications. The company also operates patient assistance programmes such as ALKare PLUS for ALK-positive NSCLC patients, digital therapeutics platforms in partnership with DoctorOnCall, and the Care-A-Van mobile community health screening programme that has reached over 156,000 lives across 800 locations over 22 years.

Pfizer Malaysia's business model is built on enterprise field sales to hospitals, clinics, and pharmacies, complemented by direct government vaccine supply contracts, partnerships with telehealth platforms (DoctorOnCall) and consumer financing partners (UOB Malaysia), and a layer of patient assistance and disease awareness programs delivered jointly with Malaysian patient advocacy organizations (LCNM, NCSM, BCWA, MTS, MRCS). Revenue mechanics are one-time license-style sales of prescription pharmaceuticals and vaccines, with pricing not publicly disclosed and patient cost addressed through programs such as ALKare PLUS and the ASK4VACCINE 12-month interest-free instalment plan. Customer segments span healthcare providers, government (JKJAV / Ministry of Health for COVID-19 vaccination), and patient populations including ALK-positive NSCLC patients, metastatic breast cancer patients and caregivers, Hajj and Umrah pilgrims, older adults aged 50+, and B40 underserved communities.

The company is led by Country Manager Luksanawan Thangpaibool (also covering Brunei) and Country Medical Director Dr. Jerusha Naidoo. It draws on the parent Pfizer Inc.'s global R&D infrastructure (25,000 clinical researchers) and benefits from Pfizer's 170+ year brand heritage and 2023 Fortune recognitions including World's Most Admired Companies All-Stars, World's Best Companies, Best Employers for New Grads, and Equality 100 Award. Geographic scope is single-country domestic, with distribution routed through direct sales, government health programs, and channel partnerships.

Pfizer Malaysia firmographics

Firmographics
Name
Pfizer Malaysia
Legal name
Pfizer Malaysia Sdn Bhd
Website
https://pfizer.com.my
Company type
Private
Founded year
1978
Operating status
Operating
Headcount range
51–100 employees
Short description
Pfizer Malaysia Sdn Bhd, the Malaysian subsidiary of Pfizer Inc., develops and commercializes innovative prescription medicines, vaccines, and patient assistance programs across oncology, vaccines, internal medicine, and rare disease for healthcare providers, government, and patients in Malaysia.
Ownership category
akta.pro rank

Pfizer Malaysia industry classification

Industry
Product category
Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAJAG
Vaccines & Cold-Chain Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRAOAHAI
Vaccines & Public Health Product Distribution

Keywords

  • Prescription pharmaceuticals
  • Biopharmaceutical medicines
  • Vaccine products
  • Cancer therapeutics
  • Patient assistance programs

Where Pfizer Malaysia is headquartered

Location

Headquarters

HQ city
Kuala Lumpur
HQ country
Malaysia
HQ region
Asia

Offices1 record

Markets served

Pfizer Malaysia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Medicines: Pfizer develops and sells innovative prescription medicines across therapeutic areas including Oncology, Inflammation & Immunology, Internal Medicine, and Rare Disease. Revenue generated through direct sales to healthcare providers and pharmacies.
  2. Vaccines: Pfizer manufactures and distributes vaccines including pneumococcal vaccines and COVID-19 vaccine. Revenue generated through government contracts and healthcare provider sales.
  3. Consumer Health Care Products: Pfizer offers consumer healthcare products as part of its global portfolio alongside prescription medicines and vaccines.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Pfizer Malaysia product offering

Product offering

Core offering

Pfizer Malaysia develops, markets, and distributes innovative prescription medicines and vaccines to healthcare providers, pharmacies, and government health programs in Malaysia. Its portfolio spans Oncology, Inflammation & Immunology, Internal Medicine, Rare Disease, and Vaccines, including specific products such as the Zavicefta antibiotic for serious Gram-negative bacterial infections and COVID-19 and pneumococcal vaccines supplied through the National Immunization Program.

Product overview

Pfizer Malaysia operates as a biopharmaceutical company within the Pfizer global network, offering a portfolio of innovative medicines, vaccines, and digital health solutions. The product portfolio includes pharmaceutical products (antibiotics such as Zavicefta), patient assistance programmes (ALKare PLUS for lung cancer patients), and mobile/community health services (Care-A-Van reaching 156,000+ lives). Pfizer Malaysia also provides digital health platforms developed in partnership with DoctorOnCall, patient education resources including the Me & mBC guide for metastatic breast cancer and lung cancer patient handbook, and disease prevention platforms like PreventPneumonia.com.my. The company focuses on therapeutic areas including Oncology, Inflammation & Immunology, Vaccines, Internal Medicine, and Rare Disease, serving healthcare professionals, patients, and the Malaysian community through integrated digital and physical health programmes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zavicefta (ceftazidime/avibactam) Novel combination antibiotic combining ceftazidime (third-generation antipseudomonal cephalosporin) with avibactam (beta-lactamase inhibitor) for treating serious Gram-negative bacterial infections in hospitalised adults aged 18 years and above. Indicated for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), Hospital-Acquired Pneumonia (HAP), and Ventilator Associated Pneumonia (VAP).
  • ALKare PLUS Patient Assistance Programme Patient assistance programme that helps ALK-positive advanced non-small cell lung cancer (NSCLC) patients in Malaysia access and continue innovative targeted therapies through financial support, treatment continuity planning, and education services.
  • Care-A-Van Mobile Health Screening Programme Mobile community health screening and outreach programme delivering healthcare awareness and basic health services to underserved and underprivileged communities in Malaysia. Has reached more than 156,000 lives across 800 locations over 22 years and covers breast health, mental health, and disease prevention education.
  • Pfizer-BioNTech COVID-19 Vaccine (Malaysian supply) Pfizer-BioNTech COVID-19 vaccine supplied to Malaysia through a partnership with JKJAV (Special Committee for Ensuring Access to Covid-19 Vaccine Supply) for deployment under the National Covid-19 Immunization Program, administered via government health channels and partner providers.
  • ASK4VACCINE Pneumococcal Vaccination Programme Pneumococcal vaccination access programme that enables Malaysian parents to obtain paediatric pneumococcal vaccination with a 12-month interest-free instalment payment plan when paying via UOB Malaysia credit cards, addressing affordability barriers to childhood immunisation.
  • Pneumococcal Vaccines (Prevenar family) for Hajj/Umrah Pilgrims and Older Adults

Quantifiable outcome

  • 156,000+ lives touched through Care-A-Van mobile health screening program across 800 locations
  • +1 more outcomes

Companies that use Pfizer Malaysia

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles3 records

Pfizer Malaysia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pfizer Malaysia partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered minor and core.

  • University of Malaya (UM)minorStrategic or Co-development Partner · 30 November 2021Partnership in University For Society (U4S) Central Zone program. UM focuses on Building Resilience for Society with mental health webinars and Construction Skills Training Module for youth community.
  • Universiti Teknologi MARA (UiTM)minorStrategic or Co-development Partner · 30 November 2021Partnership in U4S Central Zone program. UiTM runs Financial Independence Strategy for Community Entrepreneur (FISCENT) project with business networking and workshop programs.
  • International Islamic University Malaysia (IIUM)minorStrategic or Co-development Partner · 30 November 2021Partnership in U4S Central Zone program. IIUM runs Creative Youth (CR8V Youth) project and Integrated and Sustainable Agriculture Farming (InSAF) project.
  • BUMITRA MalaysiacoreGTM or Marketing Partner · 11 November 2021MOU to drive pneumococcal disease prevention awareness among Hajj and Umrah pilgrims. Campaign uses BUMITRA Malaysia Facebook page to provide information about pneumococcal pneumonia through comics, posters, infographics, and animated videos.
  • Lung Cancer Network Malaysia (LCNM)coreStrategic or Co-development Partner · 1 November 2021Partnership with LCNM and NCSM to launch Malaysia's first digital lung cancer patient handbook. The #KeepBreathing campaign improves public understanding of lung cancer and addresses misconceptions about the disease.
  • National Cancer Society Malaysia (NCSM)coreStrategic or Co-development Partner · 1 November 2021Partnership with NCSM to develop Malaysia's first digital lung cancer patient handbook to improve health literacy and facilitate better communication between patients and healthcare providers.
  • Breast Cancer Welfare Association Malaysia (BCWA)coreStrategic or Co-development Partner · 7 October 2021Support for #UNPAUSE 2021 campaign celebrating and recognizing cancer caregivers. Launch of Me & mBC digital guide and audiobook to improve metastatic breast cancer literacy and patient-caregiver communication.
  • BookDoccoreStrategic or Co-development Partner · 11 August 2021Partnership for 'Mental Health for All' digital campaign addressing mental health concerns in Malaysia. Provides resources on mental health conditions, self-assessment quizzes, and connects users to mental health specialists via tele-consult.
  • JKJAV (Special Committee for Ensuring Access to Covid-19 Vaccine Supply)coreStrategic or Co-development Partner · 1 July 2021Partnership with JKJAV under Ministry of Health and Ministry of Science, Technology and Innovation for supply and implementation of Pfizer-BioNTech COVID-19 vaccine in National Immunization Program.
  • UOB MalaysiacoreChannel Partner/ Reseller/ Distributor · 16 June 2021Malaysia's first tripartite collaboration between DoctorOnCall, Pfizer, and UOB Malaysia. The ASK4VACCINE program enables Malaysian parents to provide pneumococcal vaccination for children via a 12-month interest-free instalment payment plan for UOB Malaysia credit card holders.
  • Malaysian Thoracic Society (MTS)coreStrategic or Co-development Partner · 28 April 2021Launch of 'You Are Our Best Shot' campaign to normalize adult vaccination and improve health literacy for higher vaccination uptake among older adults. Includes digital resource hub at preventpneumonia.com.my.
  • Malaysian Red Crescent Society (MRCS)coreStrategic or Co-development Partner · 16 April 2021MOU to provide psychosocial support for Malaysians dealing with COVID-19 pandemic challenges. Programs include RedCrescent4u Careline, Care-A-Van x MyVac program for health screening in rural areas, and health webinars. Care-A-Van has touched 156,000+ lives across 800 locations.
  • DoctorOnCallcoreStrategic or Co-development Partner · 5 April 2021Pfizer collaborated with DoctorOnCall to launch a digital therapeutics platform focusing on three key therapeutic areas: smoking cessation, vaccination, and heart health. The platform includes health centers with educational content, engagement tools, and free doctor consultations.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Pfizer Malaysia competitors and assessment

Company assessment

Direct peers

  • Sanofi Malaysia: Sanofi Malaysia is the Malaysian subsidiary of Sanofi, a peer multinational pharmaceutical company. Both Pfizer Malaysia and Sanofi Malaysia operate in vaccines, specialty care, and consumer health with similar hospital and pharmacy go-to-market models.
  • Johnson & Johnson Malaysia: Johnson & Johnson Malaysia is the Malaysian subsidiary of J&J, operating across pharmaceuticals, medical devices, and consumer health. It is a close peer to Pfizer Malaysia given overlapping therapeutic areas and similar commercial model targeting hospitals and specialists.
  • AstraZeneca Malaysia: AstraZeneca Malaysia is the Malaysian subsidiary of AstraZeneca, a peer global biopharmaceutical company. Both compete in oncology, respiratory, and vaccine categories through hospital and government channels in Malaysia.
  • Novartis Malaysia: Novartis Malaysia is the Malaysian arm of Novartis, another large multinational pharma with presence in oncology, cardiovascular, and immunology. It competes directly with Pfizer Malaysia across specialty therapeutics and hospital sales channels in Malaysia.
  • Merck Sharp & Dohme (MSD) Malaysia: MSD Malaysia is the Malaysian subsidiary of Merck & Co., a direct peer in oncology, vaccines, and specialty therapeutics. Both target similar hospital, government, and pharmacy customers with comparable global pharma playbooks.
  • Boehringer Ingelheim Malaysia: Boehringer Ingelheim Malaysia is the Malaysian arm of Boehringer Ingelheim, a multinational pharma peer focused on respiratory, cardiometabolic, and specialty therapeutics. It competes with Pfizer Malaysia for hospital channel share in similar specialty care segments.
  • Bayer Malaysia: Bayer Malaysia is the Malaysian subsidiary of Bayer, a comparable multinational pharma with presence in pharmaceuticals, consumer health, and animal health. It is a relevant peer given overlap in cardiovascular and women's health therapeutic areas.
  • Eli Lilly Malaysia: Eli Lilly Malaysia is the Malaysian subsidiary of Eli Lilly, a multinational pharma peer with growing emphasis on oncology, diabetes, and immunology. Both compete for the same specialty prescriber audience in Malaysia's hospital channel.
  • GSK Malaysia: GSK Malaysia is the Malaysian subsidiary of GSK, a direct peer with a comparable vaccines and specialty pharmaceuticals portfolio. Both compete head-to-head in adult and travel vaccination markets and consumer health adjacencies in Malaysia.
  • Roche Malaysia: Roche Malaysia is the Malaysian subsidiary of Roche Holding, a peer multinational pharmaceutical company. Both are wholly-owned subsidiaries of global pharma majors operating in Malaysia with oncology, specialty therapeutics, and biologics portfolios, targeting the same hospital and government channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Pfizer Malaysia social profiles

Digital presence

Pfizer Malaysia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pfizer Malaysia leadership team

Management profile

Number of profiles

Profiles2 records

Pfizer Malaysia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pfizer Malaysia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Malaysia

What does Pfizer Malaysia do?

Pfizer Malaysia develops, markets, and distributes innovative prescription medicines and vaccines to healthcare providers, pharmacies, and government health programs in Malaysia. Its portfolio spans Oncology, Inflammation & Immunology, Internal Medicine, Rare Disease, and Vaccines, including specific products such as the Zavicefta antibiotic for serious Gram-negative bacterial infections and COVID-19 and pneumococcal vaccines supplied through the National Immunization Program.

Is Pfizer Malaysia a public or private company?

Pfizer Malaysia is a private company. It is classified as corporate owned and is currently operating.

When was Pfizer Malaysia founded?

Pfizer Malaysia was founded in 1978. It employs 51 to 100 people.

Where is Pfizer Malaysia based?

Pfizer Malaysia is headquartered in Kuala Lumpur, Malaysia, in the Asia region.

How does Pfizer Malaysia make money?

Three revenue lines are on record. Pharmaceutical Medicines are the primary driver. The others are vaccines and consumer Health Care Products.

Who are Pfizer Malaysia's main competitors?

Direct peers on record are Sanofi Malaysia, Johnson & Johnson Malaysia, AstraZeneca Malaysia, Novartis Malaysia, Merck Sharp & Dohme (MSD) Malaysia, Boehringer Ingelheim Malaysia, Bayer Malaysia, Eli Lilly Malaysia, GSK Malaysia and Roche Malaysia.

Does Pfizer Malaysia have an API?

No public API is recorded for Pfizer Malaysia.

What industry is Pfizer Malaysia in?

Pfizer Malaysia's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAJAG, Vaccines & Cold-Chain Pharmaceutical Distributors. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals